Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Essex LLC

Essex LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 731 shares of the medical research company’s stock after acquiring an additional 110 shares during the quarter. Essex LLC’s holdings in Thermo Fisher Scientific were worth $388,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Halpern Financial Inc. lifted its position in Thermo Fisher Scientific by 307.7% during the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after acquiring an additional 40 shares during the period. Coppell Advisory Solutions LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $33,000. Live Oak Investment Partners acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $36,000. Tyler Stone Wealth Management acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $37,000. Finally, Indiana Trust & Investment Management CO acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $38,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on TMO. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. HSBC began coverage on Thermo Fisher Scientific in a research note on Monday, December 18th. They set a “buy” rating and a $610.00 price objective for the company. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Robert W. Baird reiterated an “outperform” rating and set a $670.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Finally, Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $601.56.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $8.89 during mid-day trading on Friday, reaching $565.68. 400,365 shares of the stock traded hands, compared to its average volume of 1,542,342. The business has a 50-day moving average of $571.39 and a 200 day moving average of $525.37. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock has a market capitalization of $215.93 billion, a PE ratio of 36.65, a PEG ratio of 2.41 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter in the prior year, the firm earned $5.40 earnings per share. The business’s revenue was down 4.9% compared to the same quarter last year. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be given a $0.39 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO Marc N. Casper sold 5,547 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the sale, the chief executive officer now directly owns 43,608 shares in the company, valued at $24,011,436.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.